Back

DEFINE-HF and PRESERVED-HF: Dapagliflozin improves heart failure symptoms and physical limitations across the entire range of LVEF

22 May 2022 (11:37 - 11:49)
Organised by:
Congress Presentation Part of: Late-Breaking Trials - Pharmacological treatment I Pharmacotherapy HFA Premium Access Heart Failure 2022

About the speaker

Photo
Doctor Mikhail Kosiborod

St. Luke's Mid America Heart Institute, Kansas City (United States of America)

4 More presentations in this session

Presentation thumbnail
Patiromer for the management of hyperkalemia in subjects receiving renin-angiotensin-aldosterone system inhibitor medications for heart failure with reduced ejection fraction
Professor S. Anker (Berlin, DE)
Slides Video
Presentation thumbnail
DELIVER baseline and design
Professor S. Solomon (Boston, US)
Slides Video
Presentation thumbnail
HELIOS-A: 18month Exploratory Cardiac Results from the Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis
Doctor P. Garcia-Pavia (Majadahonda, ES)
Slides Video
Presentation thumbnail
GALACTIC-HF - omecamtiv mecarbil in HFrEF and low blood pressure
Professor M. Metra (Milan, IT)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Trials - Pharmacological treatment I
Video

The Event

Event poster

Heart Failure 2022

22 May 2022 11:37 CET
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023
thumbnail
Congress Session
Acute heart failure therapies: from clinical trials to clinical practice

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources